A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours

Mandair, Dalvinder; Vesely, Clare; Ensell, Leah; Lowe, Helen; Spanswick, Victoria J.; Hartley, John A.; Caplin, Martyn; Meyer, Tim

doi:10.1530/erc-16-0201

Cited by 19 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CellCollector has high capture rates in multiple cancers, including lung cancer, breast cancer, prostate cancer, head and neck cancer, and neuroendocrine tumors, and its rate of CTCs positivity is approximately 70-80%. [13][14][15][16][17] Moreover, using CellCollector, the detection rate in patients in early cancer stages is more than 50%, 20% higher than the detection rate of the similar product CellSearch. 16,18,19 The high detection rate in early-stage tumors maybe facilitates research on the application of CTCs in the diagnosis of early-stage cancer.…”

Section: Discussionmentioning

confidence: 99%

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

Duan¹,

Zhang²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) have become potential diagnostic biomarker for several types of cancer, including lung cancer. In this study, we aim to determine whether CTCs detected by CellCollector can be used for early-stage diagnosis of lung cancer. Methods: In this study, we recruited 64 volunteers, among whom 44 were suspected lung cancer patients requiring surgical treatment and 20 were healthy volunteers. We simultaneously analyzed PD-L1 expression in CTCs isolated using the GILUPI CellCollector and copy number variation by next-generation sequencing (NGS). Results: We enrolled a total of 44 patients with suspected lung cancer who required surgery and 20 healthy volunteers. The patients were classified into 4 groups based on their pathological results: benign disease, in situ cancer, microinvasive, and invasive. The CTCs detection rate for each group was 10.00% (1/10), 45% (5/11), 50% (7/14), and 67% (6/9), respectively. Among the patients with lung cancer, the CTCs detection rate increased with disease progression. The rate of CTCs positivity was 52.94% (18/34) in patients who were diagnosed with lung cancer by pathology and 10% (1/10) in patients with benign disease. CTCs were not detected in the control group. The area under the receiver operating characteristic (ROC) curve, a measure for distinguishing patients with primary lung cancer, was 0.715 (95% CI 0.549-0.880, P=0.041). The sensitivity and specificity of the in vivo CTCs detection strategy for the diagnosis of early-stage lung cancer were 52.94% and 90%, respectively. CTCs were associated with clinical pathology but not with the size and location of the nodules. Conclusion: CTCs isolation using the CellCollector in vivo detection method might be effective for distinguishing between benign and malignant nodules and may be used for early-stage diagnosis of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

Duan¹,

Zhang²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…In vivo detection methods show high CTC isolation rate (11,23). CellCollector has been shown high detection rate in lung cancer and neuroendocrine tumor (21,22). Increasing of blood volumes may overcome ex vivo limitation to increase detection rate (3).…”

Section: Discussionmentioning

confidence: 99%

“…During 30 min incubation in the arm vein of cancer patients, functional domain of CellCollector was exposed to 2–3 L of blood, which significantly improved CTC detection sensitivity. CellCollector has high detection rate in lung cancer and neuroendocrine tumor (21,22). Monitoring treatment response with changes in CTC counts detected with CellCollector shows promising potential in clinic (21).…”

Section: Introductionmentioning

confidence: 99%

Enumeration and molecular characterization of circulating tumor cell using an in vivo capture system in squamous cell carcinoma of head and neck

Zhang

Gong

Lin

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

ObjectiveDetection rate and isolation yield of circulating tumor cell (CTC) are low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches due to limited sample volumes. In this study, we applied the CellCollector to capture CTC in vivo from peripheral blood. MethodsIn total, the study included 22 cases with 37 times of detection. All of the patients were newly diagnosed with locally advanced or metastatic SCCHN, including laryngocarcinoma (40.9%, 9/22) and hypopharyngeal carcinoma (59.1%, 13/22). All patients received CTC analysis before treatment. Three patients received induction chemotherapy. Sixteen patients received surgical therapy, of which 13 patients received postoperative detection. Two patients received both induction chemotherapy and surgery treatment. Patients underwent two successive CellCollector applications 24 h before and 7 d after surgical therapy. Nine healthy volunteers were enrolled as the control group. Epidermal growth factor receptor variant type III (EGFRVIII) expression was analyzed with fluorescent dye labeled antibody.ResultsWith CellCollector isolation, 72.7% (16/22) of the patients were positive for ≥1 CTC (CTC; range, 1–17 cells) before treatments and 46.7% (7/15) of patients were CTC positive for ≥1 CTC (CTC; range, 1–29 cells) after surgical therapy. Moreover, the detection rate of CellCollector (82.4%, 14/17; CTC count range, 0–17) in advanced SCCHN (stage III–IV) was much higher than that in early stages (stage I–II, 40.0%, 2/5; CTC count range, 0–2) (P<0.05). EGFRVIII expression of CTC was also analyzed with fluorescence staining. One CTCEGFRVIII-positive patient was detected from six CTC-positive patients, and the positive expression of EGFRVIII was also found in the tumor tissue of this patient. ConclusionsIn vivo detection of CTCs had high sensitivity in SCCHN, which might improve CTC application in clinic.

show abstract

“…Authors claim that the device is exposed to ≈1 L of blood during 30 min residence in the vein. In small patient cohorts, this technology has shown greater numbers of CTCs and in more patients as compared with the CellSearch system . Complementarily, an EpCAM‐independent strategy, diagnostic leukapheresis, has been recently proposed to increase the volume of blood sampled.…”

Section: Current Outlook Of Ctcs In Liquid Biopsymentioning

confidence: 99%

Liquid Biopsy Based on Circulating Cancer‐Associated Cells: Bridging the Gap from an Emerging Concept to a Mainstream Tool in Precision Medicine

Jiménez‐Zenteno

Cerf

2019

Adv. Biosys.

View full text Add to dashboard Cite

The concept of liquid biopsy and the isolation and analysis of circulating biomarkers from blood samples is proposed as a surrogate to solid biopsies and can have the potential to revolutionize the management of patients with cancer. The relevance of circulating tumor cells (CTCs) and the importance of the information they carry is acknowledged by the medical community. But what are the barriers to clinical adoption? This review draws a panorama of the biological implications of CTCs, their physical and biochemical properties, and the current technological bottlenecks for their analysis in relation with the medical needs. Keys and considerations to bridge the technological and clinical gaps that still need to be overcome to be able to introduce CTCs in clinical routine are finally synthesized.

show abstract

A comparison of CellCollector with CellSearch in patients with neuroendocrine tumours

Cited by 19 publications

References 10 publications

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

<p>Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer</p>

Enumeration and molecular characterization of circulating tumor cell using an in vivo capture system in squamous cell carcinoma of head and neck

Liquid Biopsy Based on Circulating Cancer‐Associated Cells: Bridging the Gap from an Emerging Concept to a Mainstream Tool in Precision Medicine

Contact Info

Product

Resources

About